This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Re³ (Re-Cube: Retain Remicade® Response)(Study P04249AM3) (Re³)

This study has been terminated.
(Study enrollment was stopped due to insufficient subject accrual.)
Sponsor:
Collaborator:
Integrated Therapeutics Group
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT00394589
First received: October 31, 2006
Last updated: March 13, 2017
Last verified: March 2017
Results First Received: October 28, 2009  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Participant, Care Provider, Investigator, Outcomes Assessor;   Primary Purpose: Treatment
Condition: Rheumatoid Arthritis
Interventions: Drug: Infliximab Increased Frequency
Drug: Infliximab Increased Dose
Drug: Infliximab Control

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Increased Dose 3 mg/kg infliximab + 1 extra vial (100 mg) infliximab every 8 weeks
Increased Frequency Continuing the same dose of 3 mg/kg infliximab, but at every 6 weeks
Control Continuation of infliximab 3 mg/kg every 8 weeks

Participant Flow:   Overall Study
    Increased Dose   Increased Frequency   Control
STARTED   14   11   18 
COMPLETED   6   8   11 
NOT COMPLETED   8   3   7 
Adverse Event                2                1                2 
Lack of Efficacy                2                2                3 
Protocol Violation                4                0                2 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Increased Dose 3 mg/kg infliximab + 1 extra vial (100 mg) infliximab every 8 weeks
Increased Frequency Continuing the same dose of 3 mg/kg infliximab, but at every 6 weeks
Control Continuation of infliximab 3 mg/kg every 8 weeks
Total Total of all reporting groups

Baseline Measures
   Increased Dose   Increased Frequency   Control   Total 
Overall Participants Analyzed 
[Units: Participants]
 14   11   18   43 
Age 
[Units: Years]
Mean (Standard Deviation)
 58.7  (13.0)   58.6  (16.1)   57.7  (12.3)   58.3  (13.3) 
Sex: Female, Male 
[Units: Participants]
Count of Participants
       
Female      11  78.6%      9  81.8%      14  77.8%      34  79.1% 
Male      3  21.4%      2  18.2%      4  22.2%      9  20.9% 


  Outcome Measures

1.  Primary:   Change in Disease Activity Score Based on 28 Joint Count (DAS28) Score.   [ Time Frame: Between Screening (Week <=1) and Week 24 ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Senior Vice President, Global Clinical Development
Organization: Merck, Sharp & Dohme Corp.
e-mail: ClinicalTrialsDisclosure@merck.com



Responsible Party: Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier: NCT00394589     History of Changes
Other Study ID Numbers: P04249
Study First Received: October 31, 2006
Results First Received: October 28, 2009
Last Updated: March 13, 2017